CJC-1295 import rules in the UK

The short answer: there is no ordinary lawful route. CJC-1295 holds no marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), and it is not approved as a medicine anywhere in the world. Under the Human Medicines Regulations 2012, the statute that governs medicines in the United Kingdom, an unauthorised medicinal product may not be sold or supplied to a person in the UK^[1]. This page covers what CJC-1295 is in regulatory terms, what UK medicines law actually says, where the personal-import question sits, what happens at the border, and what the grey-market picture looks like as of July 2026.

Table of contents

1. CJC-1295's regulatory status in the UK 2. What the Human Medicines Regulations 2012 say 3. The personal-import question 4. What happens at the UK border 5. The grey-market reality 6. Prohibited in sport 7. What we do not yet know 8. Medical and regulatory disclaimer

CJC-1295's regulatory status in the UK

CJC-1295 is a long-acting analogue of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary gland to release growth hormone. The original compound, developed by ConjuChem in the mid-2000s, carries a linker that binds plasma albumin and extends its half-life. The one strong human dataset, Teichman and colleagues (2006), reported a half-life of 5.8 to 8.1 days and mean plasma growth hormone raised 2 to 10 times baseline for six days or more after a single subcutaneous dose in healthy adults^[4]. The clinical programme did not progress past early-phase work, and no regulator has authorised the compound for any indication since.

In UK terms this makes CJC-1295 an unauthorised medicinal product. The MHRA holds no marketing authorisation for it, there is no UK licensed brand, and it is not a food supplement or a cosmetic. It is also not a controlled drug under the Misuse of Drugs Act, so it does not sit in the same category as, say, anabolic steroids. That distinction matters for how the law treats it, but it does not make CJC-1295 a product a person can lawfully buy and import as a medicine.

What the Human Medicines Regulations 2012 say

The Human Medicines Regulations 2012 (SI 2012/1916) consolidate UK medicines law. Regulation 46 sets the core rule: a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product^[1]. The same regulation goes further on possession. A person may not possess an unauthorised medicinal product if they know or have reasonable cause to believe it is intended to be sold or supplied to another person in the UK^[1]. A CJC-1295 vial has no authorisation behind it, so any commercial supply of it to a UK buyer is caught by that prohibition.

Unlicensed medicines can reach UK patients, but only through tightly defined channels. A licensed importer or a holder of a Manufacturer's 'Specials' Licence can bring in an unlicensed medicine to meet the special clinical needs of an individual patient, and even then must notify the MHRA of the intended import in advance and may only proceed if the MHRA does not object^[2]. This is a regulated, clinician-led route with licensing and record-keeping behind it. It is not a self-order pathway, and a grey-market vial ordered online does not travel through it.

The personal-import question

The phrase people search for is 'personal import.' In UK practice that idea has a narrow home: a person travelling into the country may carry a modest personal supply of a medicine that has been lawfully prescribed and dispensed to them. It was built for the traveller returning with their own prescribed medication, not for mail-order purchases of a product that is unlicensed everywhere.

CJC-1295 does not fit that picture. There is no jurisdiction where it is a lawfully marketed, prescribable medicine, so there is no lawful prescription and dispensing to carry in the first place. Ordering vials from an online seller and having them posted to a UK address is a different act from carrying a personally prescribed medicine, and it is the act that UK enforcement targets.

The label on the vial does not change the analysis. 'Research use only' or 'not for human consumption' wording is common on grey-market peptide packaging, and it does not move the product out of medicines law. If a substance is presented or intended to act pharmacologically in a human being, the medicines framework applies regardless of the disclaimer printed on the box.

What happens at the UK border

Parcels entering the UK pass through Border Force, which works with the MHRA on medicines. The MHRA runs an active enforcement operation against the illegal online supply of medicines, and it publicises the results. In one investigation, the agency's Criminal Enforcement Unit secured convictions over an organised network that used multiple websites to supply unauthorised and prescription-only medicines, with charges spanning unauthorised medicines and controlled drugs^[3].

Enforcement of individual mail parcels is uneven. Volumes are high and resources are finite, so many small shipments pass without inspection. That practical reality does not change the legal position. When a parcel is flagged, the contents can be detained or destroyed, and the person named on it can be contacted by an enforcement agency. The MHRA's stated approach is to pursue the supply chains behind illegal sales rather than to treat interception as a rare event.

The grey-market reality

Online sellers, most based outside the UK, market vials described as CJC-1295 and ship to UK addresses. The legal framework above applies whatever the seller's location. The product arrives as an unauthorised medicinal product, outside the licensed routes that UK law recognises for unlicensed medicines.

There is a product-identity problem on top of the legal one. Most vials sold online as 'CJC-1295' are in fact CJC-1295 without DAC, which is the same as MOD-GRF(1-29), a short-acting peptide with a half-life closer to half an hour rather than the multi-day profile Teichman measured for the original with-DAC compound^[4]. Grey-market sellers rarely make that distinction on the product page, and identity testing in that supply chain is uncommon. A buyer chasing the published pharmacology is, in most cases, not buying the molecule that pharmacology describes. For the cross-country regulatory picture, see the CJC-1295 regulatory status by country.

Prohibited in sport

For anyone competing under the World Anti-Doping Code, there is a separate reason for caution. CJC-1295 is captured by section S2 of the WADA Prohibited List as a growth-hormone-releasing-factor analogue, alongside sermorelin and tesamorelin, and the S2 category is prohibited at all times, in and out of competition^[5]. The sport ban is independent of UK medicines law and applies even where possession would not be a domestic offence.

What we do not yet know

No sponsor has pursued a marketing authorisation for CJC-1295 since the ConjuChem programme stalled, and none has announced an intention to. There is no completed Phase 2 or Phase 3 efficacy trial, no defensible therapeutic dose range beyond the early-phase pharmacokinetic work, and no characterised long-term safety profile. Because the compound is not in any active regulatory pipeline, there is no expected date on which it might become a licensed medicine in the UK. This page will be updated if that position changes.

For the wider UK regulatory context across the peptides this site tracks, see the UK regulation hub. The single point to leave with is that UK law offers no ordinary route to import CJC-1295 as a medicine, and that the vial most sellers ship is usually not the molecule the research describes.

Medical and regulatory disclaimer

This article is for educational and journalistic purposes only. It does not constitute medical or legal advice. CJC-1295 is not an approved medicine in the United Kingdom or any jurisdiction this site tracks, and it may not be lawfully sold or supplied as a medicine under the Human Medicines Regulations 2012 as they stand. Always consult a qualified healthcare professional before considering any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Regulatory disclaimer: this page reflects our understanding of the framework as of July 2026. Regulations change. Verify with the MHRA or qualified legal counsel before making any decision based on this article. PeptideMethods.com is not a law firm and does not provide legal advice.